Camp4 Therapeutics Corporation
CAMP
$1.98
$0.3622.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -6.24% | -1.19% | -5.00% | -5.00% | |
| Gross Profit | 12.35% | -2.46% | 5.00% | 5.00% | |
| SG&A Expenses | 66.61% | 32.94% | 8.06% | 8.06% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 8.98% | 6.53% | -2.03% | -2.03% | |
| Operating Income | -4.14% | -9.55% | 2.03% | 2.03% | |
| Income Before Tax | -2.22% | -15.29% | -1.72% | -1.72% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -2.22% | -15.29% | -1.72% | -1.72% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -2.22% | -15.29% | -1.72% | -1.72% | |
| EBIT | -4.14% | -9.55% | 2.03% | 2.03% | |
| EBITDA | -4.41% | -9.99% | 2.28% | 2.28% | |
| EPS Basic | 97.46% | 17.19% | 19.87% | 19.87% | |
| Normalized Basic EPS | 97.46% | 17.19% | 19.87% | 19.87% | |
| EPS Diluted | 97.46% | 17.19% | 19.87% | 19.87% | |
| Normalized Diluted EPS | 97.46% | 17.19% | 19.87% | 19.87% | |
| Average Basic Shares Outstanding | 3,921.92% | 39.21% | 26.95% | 26.95% | |
| Average Diluted Shares Outstanding | 3,921.92% | 39.21% | 26.95% | 26.95% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |